S100A4 作为纤维化治疗点的经典DAMP
1Biosciences, Durham University, South Road, Durham, United Kingdom.
概括
S100A4是一种与损伤相关的分子模式 (DAMP),通过激活肌纤维细胞来增强炎症和纤维化. 准细胞外S100A4显示出减轻和潜在地逆转纤维化疾病的前景.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 纤维化以激活的肌纤维细胞和过度的细胞外基质沉积为特征,导致器官功能障碍.
- 损伤相关分子模式 (DAMPs) 是细胞应激或死亡期间释放的内源分子,触发炎症反应.
- 最初因其在癌症转移中的作用而被认可的S100A4现在被认为与组织纤维化有关.
研究的目的:
- 审查S100A4作为DAMP在纤维状况中的作用.
- 突出针对细胞外S100A4治疗纤维化的治疗潜力.
主要方法:
- 对S100A4,DAMPs和纤维化现有文献的审查.
- 对S100A4与收受体 (如Toll-Like Receptor 4和RAGE) 的相互作用进行分析.
- 检查使用纤维化动物模型的体内研究.
主要成果:
- 细胞外S100A4通过诱导肌纤维细胞激活和细胞外基质沉积来促进纤维化.
- S100A4作为炎症和纤维化过程的放大剂.
- 在动物模型中阻断细胞外S100A4可减轻和逆转已建立的纤维化,包括全身性硬化症.
结论:
- S100A4是一种关键的DAMP,可加剧纤维化.
- 向细胞外S100A4代表了阻止和逆转纤维化疾病的可行治疗策略.
相关概念视频
Introduction to Fibroblasts
3.1K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
Ultrasound II: Endoscopic Ultrasound and FibroScan
107
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
107
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K


